Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramelteon - Takeda

Drug Profile

Ramelteon - Takeda

Alternative Names: Ramelteon SL; Ramelteon sublingual; Rozerem; TAK-375; TAK-375SL

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer Sun Pharmaceutical Industries; Takeda
  • Class Antidementias; Antidepressants; Anxiolytics; Indenes; Mood stabilisers; Sleep disorder therapies; Small molecules
  • Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Insomnia
  • Discontinued Alzheimer's disease; Bipolar depression; Bipolar disorders; Circadian rhythm sleep disorders

Most Recent Events

  • 14 Apr 2021 Discontinued - Phase-I for Insomnia (In adolescents, In children) in USA (PO) (Takeda pipeline, April 2021)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Insomnia(In adolescents, In children) in USA (PO, Tablet)
  • 11 Sep 2015 Discontinued - Phase-III for Bipolar depression (Adjunctive treatment) in USA, United Kingdom, Poland, Bulgaria, Czech Republic, Germany, Romania, Russia, Serbia, Ukraine, Argentina, Canada, Chile, Colombia, Mexico (Sublingual) before 15 May 2015
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top